生长抑素联合乌司他丁治疗急性重症胰腺炎患者的临床分析

Patients with acute severe pancreatitis somatostatin combined clinical analysis of ulinastatin treatment

目的观察急性重症胰腺炎患者采用生长抑素联合乌司他丁治疗的临床疗效,为临床治疗提供参考。方法将81例急性重症胰腺炎患者随机分为两组,两组患者均予常规治疗合并生长抑素治疗,观察组在此基础上予乌司他丁联合治疗,比较两组患者的临床疗效。结果观察组总有效38例(92.68%),对照组总有效30例(75.00%),观察组总有效率高于对照组(χ2=4.698,P=0.030);观察组腹痛腹胀缓解时间、白细胞计数(WBC)恢复时间、血清淀粉酶(AMS)恢复时间、住院时间均少于对照组(t=3.040、2.202、2.067、2.608,P<0.05或0.01);观察组不良反应发生率为17.07%,对照组为22.50%,两组差异无显著性(χ2=0.376,P=0.539)。结论急性重症胰腺炎患者采用生长抑素联合乌司他丁治疗效果优于单用生长抑素,且起效快。

Objective To observe the patients with severe acute pancreatitis with somatostatin combined the clinical curative effect of ulinastatin treatment, provide reference for clinical. Methods 81 patients with acute severe pancreatitis were randomly divided into two groups, two groups of both the conventional medicine combined somatostatin therapy, the observing group on the basis of this to the ulinastatin combined treatment, compared two groups of clinical curative effect. Results The total effective observation group 38 cases (92.68%), 30 cases (75.00%), control group total effective observation group total effective rate was higher than the control group (χ2 = 4.698, P = 4.698). Abdominal pain, abdominal distension relief time observing group, the WBC recovery time, AMS recovery time, hospital stay is less than the control group (t=3.040, 2.202, 2.067, 2.202, P<0.05 or 0.01);Experimental group 17.07%incidence of adverse reactions, the control group was 17.07%, no statistically signiifcant differences between the two groups (χ2=0.376, P=0.376). Conclusion Patients with severe acute pancreatitis with somatostatin combined ulinastatin treatment the curative effect is superior to the use of somatostatin, and take effect quickly.